TNXP_OUT_1 [2025-04-01 07:50:23 -0400] 2710 Bytes | 759 tokens | Cum: 759 tkns (9.49% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Tonix Pharmaceuticals (TNXP) hit my radar screen, up to 20.77 from a prev close of 17.875 Do you think its got more juice or is it lacking potential? It's 7:50:22 AM on Tue Apr 01, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Tonix Pharmaceuticals:

C1 - Today 07:00AM - Tonix Pharmaceuticals Launches TONIX ONE , a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
C2 - Mar-31-25 07:00AM - Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
C3 - Mar-27-25 07:00AM - Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
C4 - Mar-26-25 02:30AM - Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years
C5 - Mar-25-25 01:00PM - Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic
C6 - Mar-25-25 01:00PM 09:10AM - Pharma Frenzy: Volatility Ignites Biotech Sector
C7 - Mar-24-25 08:00AM - Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia
C8 - Mar-20-25 07:00AM - As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

Prior AI Reports for TNXP:
1. 2025-03-24 – Score: 65 – Target: 30.0000 – Highs: 37.8300 / 31.5000 / 31.87
tonix-pharmaceuticals-shows-volatility-potential-for-short-term-upside-looms
2. 2025-03-21 – Score: 72 – Target: 30.0000 – Highs: 23.9837 / 37.8300 / 31.50
tonix-pharmaceuticals-high-volatility-amid-concerning-financial-health

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Tonix Pharmaceuticals (TNXP)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TNXP_OUT_3 [2025-04-01 07:50:29 -0400] 776 Bytes | 238 tokens | Cum: 999 tkns (12.49% of 8k)
==========================================================================

Showing C4 (chunk 1 of 1): C4:
**Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years**
Date: Mar-26-25 02:30AM
Source: (SeekingAlpha)
URL: https://seekingalpha.com/article/4770421-tonix-pharmaceuticals-potential-to-have-first-new-fibromyalgia-drug-in-15-years?utm_source=finviz.com&utm_medium=referral&feed_item_type=article

Error fetching article: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4770421-tonix-pharmaceuticals-potential-to-have-first-new-fibromyalgia-drug-in-15-years?utm_source=finviz.com&utm_medium=referral&feed_item_type=article

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TNXP_OUT_5 [2025-04-01 07:50:29 -0400] 1043 Bytes | 294 tokens | Cum: 1411 tkns (17.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T11:21:20Z - Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Pati...
A2 - 2025-04-01T11:00:00Z - Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Pati...
A3 - 2025-03-31T11:00:00Z - Tonix's Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Lat...
A4 - 2025-03-31T11:02:00Z - Tonix Pharmaceuticals Holding: Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia ...
A5 - 2025-03-29T12:42:06Z - New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Fe...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TNXP_OUT_7 [2025-04-01 07:50:32 -0400] 1101 Bytes | 305 tokens | Cum: 1718 tkns (21.48% of 8k)
==========================================================================

Showing A1 (chunk 1 of 16): A1:
**Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition**Date: 2025-04-01Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/01/tmt-newswire/globenewswire/tonix-pharmaceuticals-launches-tonix-onea-fully-integrated-digital-platform-designed-to-help-patients-better-understand-and-manage-their-migraine-condition/2084201Rio Silver Pivots to High-Grade Silver Exploration / Exploitation - Announces Executive Changes

Tonix expands its all-in-one platform, partnering with the world's leading migraine diary app, enhancing disease education and prescription access

CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of market

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TNXP_OUT_9 [2025-04-01 07:50:33 -0400] 993 Bytes | 298 tokens | Cum: 2089 tkns (26.11% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-26T16:31:00Z - 2 Stocks Riding the Biotech Surge With Major Catalysts Ahead
B2 - 2025-03-11T11:00:00Z - Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th
B3 - 2025-03-03T18:00:00Z - Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of ~24% by 2032 | DelveInsight
B4 - 2025-02-05T12:00:00Z - Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
B5 - 2024-11-26T12:00:00Z - Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
B6 - 2024-11-01T11:00:00Z - Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_11 [2025-04-01 07:50:36 -0400] 716 Bytes | 177 tokens | Cum: 2268 tkns (28.35% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**2 Stocks Riding the Biotech Surge With Major Catalysts Ahead**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/2-stocks-riding-the-biotech-surge-with-major-catalysts-ahead-200658754The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TNXP_OUT_13 [2025-04-01 07:50:37 -0400] 1151 Bytes | 304 tokens | Cum: 2619 tkns (32.74% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 8-K Item 7.01 Regulation FD Disclosure. On April 1, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced the launch of TONIX ONE, a digital platform for migraine patients. A copy of the press release that discusses this matter is furnished hereto as Exhibit 99.01, and in...

S2 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure. On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Companys New Drug Application (NDA) for its TNX-102 SL...

S3 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure. On March 24, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Companys New Drug Application (NDA) for its TNX-102 SL...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TNXP_OUT_15 [2025-04-01 07:50:42 -0400] 1098 Bytes | 278 tokens | Cum: 2899 tkns (36.24% of 8k)
==========================================================================

Showing S1 (chunk 1 of 3): S1:
Item 7.01 Regulation FD Disclosure. On April 1, 2025, Tonix Pharmaceuticals Holding Corp. (the Company) announced the launch of TONIX ONE, a digital platform for migraine patients. A copy of the press release that discusses this matter is furnished hereto as Exhibit 99.01, and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed filed for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 On April 1, 2025, the Company announced the launch of TONIX ONE.

F

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TNXP_OUT_17 [2025-04-01 07:50:53 -0400] 4245 Bytes | 1210 tokens | Cum: 4226 tkns (52.83% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 1,891,769 | Perf Month: 127.42% | Option/Short: No / Yes | Sales Y/Y TTM: 29.94% |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 1.69M | Perf Quarter: -51.69% | Short Float: 13.66% | ROE: -106.12% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 1.13 | Index: - | Short Ratio: 0.52 | ROI: -89.94% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 48.16 | Market Cap: 115.02M | Short Interest: 0.88M | Sales Surprise: -19.31% |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 4.52 | Shs Outstand: 6.43M | Beta: 1.51 | EPS Surprise: 47.19% |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: -1.74% | Shs Float: 6.43M | Sales Q/Q: -31.68% | P/E: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: -5.45% | Inst Own: 2.48% | Sales past 5Y: 5.99% | Earnings: Mar 18 AMC |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -44.58% | Insider Own: 0.00% | Employees: 81 | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -41.41% | Insider Trans: - | Debt/Eq: 0.06 | |
+--------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 10094000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -130036000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 17.875
Average Volume: 2479878.1
30-Day High: 30.51
30-Day Low: 7.38

[Detailed Financials: TTM 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: TTM 2024]
- Revenue: $10,094,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $73,831,000.0

[Detailed Financials: FY 2024]
- Total Assets: $162,890,000.0
- Total Liabilities: $23,332,000.0
- Total Equity: $139,558,000.0
- Current Assets: $119,002,000.0
- Current Liabilities: $18,307,000.0

[Income Statement: FY 2024]
- Revenue: $10,094,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -176.6

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $73,831,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TNXP_OUT_19 [2025-04-01 07:50:55 -0400] 676 Bytes | 167 tokens | Cum: 4650 tkns (58.13% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TNXP_IN_21 [2025-04-01 07:50:55 -0400] 126 Bytes | 29 tokens | Cum: 4707 tkns (58.84% of 8k)
==========================================================================

====================================
[2025-04-01 07:50:55] # Analysis Completed
Elapsed Time: 33.37 seconds